NEO trial: neoadjuvant olaparib in platinum-sensitive relapsed high-grade serous ovarian cancer скачать в хорошем качестве

NEO trial: neoadjuvant olaparib in platinum-sensitive relapsed high-grade serous ovarian cancer

Stephanie Lheureux, MD, PhD, University of Toronto, Toronto, Canada, discusses the Phase II NEO study (NCT02489006), which evaluates the feasibility of using olaparib, a PARP inhibitor, as a neo-adjuvant therapy before secondary cytoreductive surgery in patients with recurrent platinum-sensitive high-grade serous ovarian cancer (HGSOC). This Phase II trial involved 44 patients randomized to receive either 6 cycles of platinum chemotherapy followed by maintenance olaparib (Arm A) or olaparib alone (Arm B). The study found that olaparib alone post-surgery was as effective as the combination therapy, with similar progression-free survival (PFS) and overall survival (OS) rates, but with fewer side effects. This suggests a potential chemo-free treatment approach for selected patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.